Efficacy of Antifungal Therapy in a Nonneutropenic Murine Model of Zygomycosis
Open Access
- 1 June 2002
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (6) , 1953-1959
- https://doi.org/10.1128/aac.46.6.1953-1959.2002
Abstract
Three isolates of zygomycetes belonging to three different genera ( Rhizopus microsporus , Absidia corymbifera , and Apophysomyces elegans ) were used to produce a disseminated infection in nonimmunocompromised mice. The therapeutic efficacy of amphotericin B, given intraperitoneally at doses ranging from 0.5 to 4.5 mg/kg of body weight/day, oral itraconazole at 100 mg/kg/day, and oral terbinafine at 150 mg/kg/day was evaluated in this model. The markers of antifungal efficacy were the median survival time, the mortality rate, and the percentage of infected organs. Organ culture was performed along with microscopic direct examinations of tissues to assess the presence of an active infection. An acute and lethal infection was obtained in untreated mice challenged with each of the three strains. The data obtained for direct examinations and qualitative cultures indicate that, due to the nonseptate nature of the hyphae, each technique gives different information and should be used together with the others. Against all three strains, amphotericin B yielded a 90 to 100% survival rate. Itraconazole was inactive against R. microsporus but significantly reduced mortality in mice infected with A. corymbifera or A. elegans. Terbinafine had no beneficial effects against R. microsporus and A. corymbifera despite documented absorption of the drug. Overall, only limited correlations were observed between MICs determined in vitro and in vivo efficacy of the drugs. The efficacy of itraconazole in these models of zygomycosis suggests that this drug, as well as the new azole compounds presently under development, warrants close evaluation.Keywords
This publication has 35 references indexed in Scilit:
- In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimensMycopathologia, 1994
- Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drugJournal of Antimicrobial Chemotherapy, 1994
- Medical mycologyRevista do Instituto de Medicina Tropical de São Paulo, 1992
- Cure of Zygomycosis Caused by a Lipase-producing Rhizopus rhizopodiformis Strain in a Renal Transplant PatientScandinavian Journal of Infectious Diseases, 1991
- Inactivity of terbinafine in a rat model of pulmonary aspergillosisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Treatment of Experimental Zygomycosis in Guinea Pigs with Azoles and with Amphotericin BChemotherapy, 1989
- Experimental Zygomycosis Due to Rhizopus spp. Infection by Various Routes in Guinea‐Pigs, Rats and MiceMycoses, 1988
- In vitro and in vivo Drug Studies with Three Agents of Central Nervous System PhaeohyphomycosisChemotherapy, 1987
- In Vivo Bronchoalveolar Macrophage Defense Against Rhizopus oryzae and Aspergillus fumigatusThe Journal of Infectious Diseases, 1984
- FACTORS DETERMINING THE SUSCEPTIBILITY OF MICE TO EXPERIMENTAL PHYCOMYCOSISJournal of Medical Microbiology, 1975